The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
S100A8/A9 as a potent serological marker in monitoring the activity of chemotherapy in pancreatic cancer.
 
Shuichi Mitsunaga
Speakers' Bureau - Eisai
Research Funding - Chugai Pharma
Patents, Royalties, Other Intellectual Property - Chugai Pharma
 
Masafumi Ikeda
Consulting or Advisory Role - NanoCarrier
Speakers' Bureau - Abbott Diagnostics; Bayer Yakuhin; Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Guerbet; Kyowa Hakko Kirin; Merck Serono; Novartis; Takeda; Yakult Pharmaceutical
Research Funding - Bayer Yakuhin; Boehringer Ingelheim; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; GlaxoSmithKline; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Novartis; OncoTherapy Science; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical
 
Satoshi Shimizu
No Relationships to Disclose
 
Izumi Ohno
No Relationships to Disclose
 
Hideaki Takahashi
No Relationships to Disclose
 
Hiroyuki Okuyama
No Relationships to Disclose
 
Yusuke Hashimoto
No Relationships to Disclose
 
Kazuo Watanabe
No Relationships to Disclose
 
Kumiko Umemoto
No Relationships to Disclose
 
Atsushi Ochiai
Honoraria - Astellas Pharma; Chugai Pharma; DAKO; Lilly Japan; Roche Pharma AG; Taiho Pharmaceutical; Takeda; Toray Industries
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly Japan; Otsuka; Roche Pharma AG; Takeda
Patents, Royalties, Other Intellectual Property - Chugai Pharma